HIV molecular immunology database
PQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVG
|
Pol(305-345) | mouse epitope |
AIFQSSMTKILEPFRKQN
|
Pol(313-330) | human epitope |
AIFQSSMTKILEPFRKQNPDIVIYQ
|
Pol(313-337) | A11 human epitope |
AIFQSSMTKILEPFRKQNPDIVIYQ
|
Pol(313-337) | A11 human epitope |
SMTKILEPFRAQNPE
|
Pol(318-332) | human epitope |
KILEPFRKQNPDIVIYQY
|
Pol(321-338) | human epitope |
KILEPFRKQNPDIVIYQY
|
Pol(321-338) | human epitope |
ILEPFRAQNPEIVIY
|
Pol(322-336) | human epitope |
ILEPFRAQNPEIVIY
|
Pol(322-336) | human epitope |
ILEPFRAQNPEIVIY
|
Pol(322-336) | human epitope |
FRKQNPDIV
|
Pol(326-334) | human epitope |
FRAQNPEIVIY
|
Pol(326-336) | human epitope |
FRAQNPEIVIYQYMDKK
|
Pol(326-342) | human epitope |
FRAQNPEIVIYQYMDKK
|
Pol(326-342) | human epitope |
FRAQNPEIVIYQYMDKK
|
Pol(326-342) | human epitope |
RAQNPEIVIY
|
Pol(327-336) | human epitope |
RAQNPEIVIYQYMDDLYV
|
Pol(327-344) | C*12 human epitope |
KQNPDIVIY
|
Pol(328-336) | A*30 human epitope |
AQNPEIVIY
|
Pol(328-336) | A*30 human epitope |
ArNPEIVIY
|
Pol(328-336) | observed variant |
AkNPEIVIY
|
Pol(328-336) | observed variant |
AQNPEIVIc
|
Pol(328-336) | observed variant |
AQNPElVIY
|
Pol(328-336) | observed variant |
tQNPEIVIY
|
Pol(328-336) | observed variant |
KQNPDIVIY
|
Pol(328-336) | A30 human epitope |
KQNPDIVIY
|
Pol(328-336) | A30 human epitope |
AQNPEIVIY
|
Pol(328-336) | A*30:02 human epitope |
KQNPDIVIY
|
Pol(328-336) | A*30:02 human epitope |
KQNPDIVIY
|
Pol(328-336) | A*30:02 human epitope |
KQNPDIVIY
|
Pol(328-336) | B*15:01 human epitope |
KQNPDIVIY
|
Pol(328-336) | B*15:03 human epitope |
KQNPDIVIY
|
Pol(328-336) | B*15:03 human epitope |
KQNPeIVIY
|
Pol(328-336) | subtype-specific non-susceptible form |
KQNPDIVIY
|
Pol(328-336) | B*18 human epitope |
KQNPDIVIY
|
Pol(328-336) | B*35:02, B*35:03, B*53:01 human epitope |
KQNPDIVIY
|
Pol(328-336) | C*12:02 human epitope |
KQNPDIVIi
|
Pol(328-336) | diminished HLA binding or increased off-rate; non-susceptible form |
KQNPDIVIv
|
Pol(328-336) | diminished HLA binding or increased off-rate; diminished response; non-susceptible form |
KQNPDIVIc
|
Pol(328-336) | diminished HLA binding or increased off-rate; diminished response; non-susceptible form |
KQNPDIVIY
|
Pol(328-336) | C*12:02 human epitope |
KQNPDIVIY
|
Pol(328-336) | C*12:02 human epitope |
KQNPDIVIY
|
Pol(328-336) | C*12:02 human epitope |
KQNPDIVIC
|
Pol(328-336) | human epitope |
KQNPDIVIy
|
Pol(328-336) | observed variant |
KQNPDIVIY
|
Pol(328-336) | human epitope |
KQNPDIVIc
|
Pol(328-336) | drug induced; observed variant |
AQNPEIVIY
|
Pol(328-336) | human epitope |
KQNPDIVIY
|
Pol(328-336) | human epitope |
KQNPDIVIYQY
|
Pol(328-338) | A*24 human epitope |
KQNPDIVIYQY
|
Pol(328-338) | A*30 human epitope |
AQNPEIVIYQY
|
Pol(328-338) | A*30:02 human epitope |
KQNPDIVIYQY
|
Pol(328-338) | B*15:01 human epitope |
KQNPDIVIYQY
|
Pol(328-338) | B*15:03 human epitope |
KQNPDIVIYQY
|
Pol(328-338) | B*35:02, B*35:03, B*53:01 human epitope |
KQNPDIVIYQY
|
Pol(328-338) | human epitope |
QNPDIVIYQ
|
Pol(329-337) | human epitope |
KNPEIVIYQYMDDLYV
|
Pol(329-344) | human epitope |
KNPEIVIYQYMDDLYV
|
Pol(329-344) | macaque epitope |
KNPEIVIYQYMDDLYV
|
Pol(329-344) | human epitope |
KNPEIVIYQYMDDLYV
|
Pol(329-344) | human epitope |
QNPDIVIYQYMDDLYVGS
|
Pol(329-346) | human epitope |
NPDIVIQYQ
|
Pol(330-337) | A30 human epitope |
NPDIVIYQY
|
Pol(330-338) | A*36 human epitope |
NPEIVIYQY
|
Pol(330-338) | B*18 human epitope |
NPDIVIYQY
|
Pol(330-338) | B*18 human epitope |
NPEIVIYQY
|
Pol(330-338) | B*18 human epitope |
NPEIVIYQY
|
Pol(330-338) | B*18 human epitope |
NPDIVIYQY
|
Pol(330-338) | B*27 human epitope |
NPDWIYQY
|
Pol(330-338) | B*35 human epitope |
HPDIVIYQY
|
Pol(330-338) | B*35 human epitope |
NPEIVIYQY
|
Pol(330-338) | B*35 human epitope |
HPDIVIYQY
|
Pol(330-338) | B*35 human epitope |
NPDIVIYQY
|
Pol(330-338) | B*35 human epitope |
HPDIVIYQY
|
Pol(330-338) | B*35 human epitope |
NPDIVIYQY
|
Pol(330-338) | B*35 epitope |
HPDIVIYQY
|
Pol(330-338) | B35 human epitope |
HPDIVIYQY
|
Pol(330-338) | B35 human epitope |
HPDIVIYQY
|
Pol(330-338) | B35 human epitope |
NPDIVIYQY
|
Pol(330-338) | B35 human epitope |
NPeIVIYQY
|
Pol(330-338) | diminished HLA binding or increased off-rate |
HPDIVIYQY
|
Pol(330-338) | B35 human epitope |
NPDIVIYQY
|
Pol(330-338) | B35 human epitope |
NPDIVIYQY
|
Pol(330-338) | B35 human epitope |
hPDIVIYQY
|
Pol(330-338) | susceptible form |
hPDIlIYQY
|
Pol(330-338) | susceptible form |
NPDIiIYQY
|
Pol(330-338) | susceptible form |
NPeIVIYQY
|
Pol(330-338) | susceptible form |
NPDlVIYQY
|
Pol(330-338) | susceptible form |
NPDIVIYQY
|
Pol(330-338) | B35 human epitope |
NPeIVIYQY
|
Pol(330-338) | diminished HLA binding or increased off-rate; susceptible form |
NPDlVIYQY
|
Pol(330-338) | susceptible form |
NPDIiIYQY
|
Pol(330-338) | diminished HLA binding or increased off-rate; susceptible form |
NPDIVIYQY
|
Pol(330-338) | B35 human epitope |
hPDIVIYQY
|
Pol(330-338) | observed variant |
NPeIVIYQY
|
Pol(330-338) | observed variant |
HPDIVIYQY
|
Pol(330-338) | B35 human epitope |
HPDIVIYQY
|
Pol(330-338) | B35 human epitope |
HPDIVIYQY
|
Pol(330-338) | B35 human epitope |
NPDIVIYQY
|
Pol(330-338) | B35 human epitope |
HPDIVIYQY
|
Pol(330-338) | B35 human epitope |
nPDIVIYQY
|
Pol(330-338) | susceptible form |
NPDIVIYQY
|
Pol(330-338) | B35 human epitope |
HPDIVIYQY
|
Pol(330-338) | B35 human, macaque epitope |
HPDIVIYQY
|
Pol(330-338) | B35 human epitope |
NPDIVIYQY
|
Pol(330-338) | B35 human epitope |
NPDIVIYQY
|
Pol(330-338) | B35 human epitope |
NPDVILIQY
|
Pol(330-338) | B35 human epitope |
NPDIVIYQY
|
Pol(330-338) | B35 human epitope |
NPDIVIYQY
|
Pol(330-338) | B35 human epitope |
NPDIVIYQY
|
Pol(330-338) | B35 human epitope |
NPDIVIYQY
|
Pol(330-338) | B*35:01 human epitope |
NPEIVIYQY
|
Pol(330-338) | B*35:01 human epitope |
HPDIVIYQY
|
Pol(330-338) | B*35:01 human epitope |
NPDIVIYQY
|
Pol(330-338) | B*35:01 human epitope |
HPDIVIYQY
|
Pol(330-338) | B*35:01 human epitope |
NPEIVIYQY
|
Pol(330-338) | B*35:01 human epitope |
NPEIVIiQY
|
Pol(330-338) | diminished response; susceptible form |
NPEIVIvQY
|
Pol(330-338) | diminished response; susceptible form |
NPEIVIcQY
|
Pol(330-338) | diminished response; susceptible form |
NPDIVIYQY
|
Pol(330-338) | B*35:01 human epitope |
NPDIVIYQY
|
Pol(330-338) | B*35:01 human epitope |
NPDIVIYQY
|
Pol(330-338) | B*35:01 human epitope |
NPDIVIiQY
|
Pol(330-338) | diminished HLA binding or increased off-rate; diminished response; non-susceptible form |
NPDIVIvQY
|
Pol(330-338) | diminished HLA binding or increased off-rate; diminished response; non-susceptible form |
NPDIVIcQY
|
Pol(330-338) | diminished HLA binding or increased off-rate; diminished response; non-susceptible form |
NPDIVIYQY
|
Pol(330-338) | B*35:01 human epitope |
NPDIVIYQY
|
Pol(330-338) | B*35:01 human epitope |
NPDIVIYQY
|
Pol(330-338) | B*35:01 human epitope |
NPxIVIYQY
|
Pol(330-338) | calculated escape; literature escape |
NPEIVIYQY
|
Pol(330-338) | B*35:01, B*35:08 human epitope |
NPEIVIYQY
|
Pol(330-338) | B*35:02, B*35:03, B*53:01 human epitope |
HPDIVIYQY
|
Pol(330-338) | B*35:02, B*35:03, B*53:01 human epitope |
NPDIVIYQY
|
Pol(330-338) | B*35:02, B*35:03, B*53:01 human epitope |
NPEIVIYQY
|
Pol(330-338) | B*42:01 human epitope |
NPEIVIYQY
|
Pol(330-338) | C*07 human epitope |
HPDIVIYQY
|
Pol(330-338) | C*12 human epitope |
NPDIVIYQY
|
Pol(330-338) | human epitope |
NPDIVIYQY
|
Pol(330-338) | human epitope |
NPDIVIYQYM
|
Pol(330-339) | B51 human epitope |
NPDIVIYQYv
|
Pol(330-339) | drug induced; susceptible form |
NPDIVICQYM
|
Pol(330-339) | human epitope |
NPDIVIyQYM
|
Pol(330-339) | observed variant |
NPDIVIYQYMDDLYVGSDLEIGQHR
|
Pol(330-354) | A11 human epitope |
PEIVIYQYM
|
Pol(331-339) | B*18:01 human epitope |
PEIVIYDYM
|
Pol(331-339) | B*18:01, E*01:01, E*01:03 human epitope |
EIVIYQYMD
|
Pol(332-340) | B*18:01 human epitope |
EIVIYQYMD
|
Pol(332-340) | B*18:01 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02 human epitope |
VIYQYvDDL
|
Pol(334-342) | non-susceptible form |
VIYQYMDDL
|
Pol(334-342) | A*02 human epitope |
VIVQYMDDL
|
Pol(334-342) | A*02 human epitope |
VIYQYNDDL
|
Pol(334-342) | A*02 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02 human epitope |
VIYQYMMDL
|
Pol(334-342) | A*02 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02 human epitope |
iIYQYMDDL
|
Pol(334-342) | observed variant |
VIcQYMDDL
|
Pol(334-342) | observed variant |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human, macaque epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 mouse epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 mouse epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 mouse epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human epitope |
VIYQYvDDL
|
Pol(334-342) | drug induced; escape documented in this paper |
tIYQYMDDL
|
Pol(334-342) | drug induced; susceptible form |
iIYQYMDDL
|
Pol(334-342) | drug induced; susceptible form |
eIYQYMDDL
|
Pol(334-342) | drug induced; escape documented in this paper |
VIcQYMDDL
|
Pol(334-342) | drug induced; diminished response |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 humanized mouse epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human epitope |
VIYQYMDDL
|
Pol(334-342) | A*02:01 human epitope |
tIYQYMDDL
|
Pol(334-342) | drug induced; susceptible form |
iIYQYMDDL
|
Pol(334-342) | drug induced; susceptible form |
eIYQYMDDL
|
Pol(334-342) | drug induced; escape documented in this paper |
VIYQYvDDL
|
Pol(334-342) | drug induced; escape documented in this paper |
VIcQYMDDL
|
Pol(334-342) | drug induced; diminished response |
VIYQYMDDL
|
Pol(334-342) | A*02:01, A2 human epitope |
cIYQYMDDL
|
Pol(334-342) | observed variant |
VIYQYMMDL
|
Pol(334-342) | A*02:02, A2 human epitope |
VIYQYMDDL
|
Pol(334-342) | A2 human epitope |
VIYQYMDDL
|
Pol(334-342) | A2 human epitope |
VIYQYMDDL
|
Pol(334-342) | A2 transgenic mouse epitope |
VIYQYMDDL
|
Pol(334-342) | A2 human epitope |
VIYQYMDDL
|
Pol(334-342) | A2 transgenic mouse epitope |
VIYQYMDDL
|
Pol(334-342) | A2 human epitope |
VIYQMDDL
|
Pol(334-342) | A2 human epitope |
VIYQYMDDL
|
Pol(334-342) | A2 human epitope |
VIcQYMDDL
|
Pol(334-342) | drug induced; susceptible form |
VIYQYvDDL
|
Pol(334-342) | drug induced; susceptible form |
VIcQYvDDL
|
Pol(334-342) | drug induced; susceptible form |
VIYQYMDDL
|
Pol(334-342) | A2 human epitope |
VIYQYMDDL
|
Pol(334-342) | A2 human epitope |
VIYQYMDDL
|
Pol(334-342) | A2 human epitope |
VIYQYMDDL
|
Pol(334-342) | A2 human epitope |
VIYQYMDDL
|
Pol(334-342) | A2 human epitope |
VIYQYMDDL
|
Pol(334-342) | A2 human epitope |
VIYQYvDDL
|
Pol(334-342) | drug induced; susceptible form |
VIYQYiDDL
|
Pol(334-342) | drug induced; susceptible form |
iIYQYvDDL
|
Pol(334-342) | observed variant |
VIYQYMMDL
|
Pol(334-342) | A2 human epitope |
VIYQYMDDL
|
Pol(334-342) | A2 human epitope |
VIYQYMDDL
|
Pol(334-342) | A2 human epitope |
VIYQYMDDL
|
Pol(334-342) | B*35:02, B*35:03, B*53:01 human epitope |
VIYQYMDDL
|
Pol(334-342) | B*51 human epitope |
VIYQYMDDLYV
|
Pol(334-344) | A*02:01 human epitope |
VIYQYMDDLYV
|
Pol(334-344) | A*02:01 human epitope |
VIYQYVDDLYV
|
Pol(334-344) | A*02:01 human epitope |
VIYQYMDDLYV
|
Pol(334-344) | A*02:01 human epitope |
VIYQYvDDLYV
|
Pol(334-344) | inferred escape |
VIYQYMDDLYV
|
Pol(334-344) | A*02:01 human epitope |
VIYQYMDDLYV
|
Pol(334-344) | A*02:01 human epitope |
VIYQYMDDLYVGSDL
|
Pol(334-348) | human epitope |
VIYQYMDDLYVGSDL
|
Pol(334-348) | human epitope |
IYQYMDDL
|
Pol(335-342) | C*08:01 human epitope |
IYQYMDDLYV
|
Pol(335-344) | A*02:01 human epitope |
IYQYMDDLYV
|
Pol(335-344) | A*02:01 humanized mouse epitope |
IYQYvDDLYV
|
Pol(335-344) | subtype-specific susceptible form |
IYQYMDDLYi
|
Pol(335-344) | subtype-specific susceptible form |
IYsYMDDLYV
|
Pol(335-344) | subtype-specific susceptible form |
IcQYMDDLYV
|
Pol(335-344) | subtype-specific susceptible form |
IYQYMDDLYV
|
Pol(335-344) | A*02:01 human epitope |
IYQYMDDLYV
|
Pol(335-344) | A*02:01 human epitope |
IcQYMDDLYV
|
Pol(335-344) | diminished response; non-susceptible form |
IvQYMDDLYV
|
Pol(335-344) | diminished response; non-susceptible form |
IiQYMDDLYV
|
Pol(335-344) | diminished response; non-susceptible form |
YQYMDDLYV
|
Pol(336-344) | A*02 human epitope |
YQYvDDLYV
|
Pol(336-344) | non-susceptible form; susceptible form |
YQYMDDLYV
|
Pol(336-344) | A*02 human epitope |
YQYVDDLYV
|
Pol(336-344) | A*02 human epitope |
YQYmDDLYV
|
Pol(336-344) | observed variant |
YQYMDDLYV
|
Pol(336-344) | A*02 human epitope |
YQYvDDLYV
|
Pol(336-344) | drug induced; observed variant |
YQYMDDLYV
|
Pol(336-344) | A*02 human epitope |
YQYVDDLYV
|
Pol(336-344) | A*02:01 human epitope |
YQYMDDLYV
|
Pol(336-344) | A*02:01 humanized mouse epitope |
YQYvDDLYV
|
Pol(336-344) | subtype-specific susceptible form |
YQYMDDLYi
|
Pol(336-344) | subtype-specific susceptible form |
cQYMDDLYV
|
Pol(336-344) | subtype-specific susceptible form |
YQYMDDLYV
|
Pol(336-344) | A*02:01 human epitope |
YQYMDDLYV
|
Pol(336-344) | A*02:01 human epitope |
YQYMDDLYV
|
Pol(336-344) | A*02:01 human epitope |
YQYvDDLYV
|
Pol(336-344) | drug induced; susceptible form |
YQYMDDLYV
|
Pol(336-344) | A*02:01 human epitope |
YQYMDDLYV
|
Pol(336-344) | A*02:01 human epitope |
YQYvDDLYV
|
Pol(336-344) | inferred escape |
YQYMDDLYV
|
Pol(336-344) | A*02:01 human epitope |
YQYMDDLYV
|
Pol(336-344) | A*02:01 human epitope |
YQYMDDLYV
|
Pol(336-344) | A*02:01 human epitope |
YQYMDDLYV
|
Pol(336-344) | A*02:01 human epitope |
QYMDDLYV
|
Pol(337-344) | A*02:01 human epitope |